Therasense Stock Probability of Future Pink Sheet Price Finishing Under 0.00

THER Stock  USD 0.0001  0.00  0.00%   
Therasense's future price is the expected price of Therasense instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Therasense performance during a given time horizon utilizing its historical volatility. Check out Therasense Backtesting, Therasense Valuation, Therasense Correlation, Therasense Hype Analysis, Therasense Volatility, Therasense History as well as Therasense Performance.
  
Please specify Therasense's target price for which you would like Therasense odds to be computed.

Therasense Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Therasense for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Therasense can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Therasense generated a negative expected return over the last 90 days
Therasense has some characteristics of a very speculative penny stock
Therasense has a very high chance of going through financial distress in the upcoming years
Therasense currently holds 2.9 M in liabilities. Therasense has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Therasense until it has trouble settling it off, either with new capital or with free cash flow. So, Therasense's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Therasense sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Therasense to invest in growth at high rates of return. When we think about Therasense's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 353.26 K. Net Loss for the year was (7.75 M) with profit before overhead, payroll, taxes, and interest of 256.68 K.
Therasense currently holds about 127.82 K in cash with (5.54 M) of positive cash flow from operations.
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Latest headline from finance.yahoo.com: Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3

Therasense Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Therasense Pink Sheet often depends not only on the future outlook of the current and potential Therasense's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Therasense's indicators that are reflective of the short sentiment are summarized in the table below.
Float Shares1.01B
Average Daily Volume Last 10 Day1.1M
Average Daily Volume In Three Month1.02M

Therasense Technical Analysis

Therasense's future price can be derived by breaking down and analyzing its technical indicators over time. Therasense Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Therasense. In general, you should focus on analyzing Therasense Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Therasense Predictive Forecast Models

Therasense's time-series forecasting models is one of many Therasense's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Therasense's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Therasense

Checking the ongoing alerts about Therasense for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Therasense help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Therasense generated a negative expected return over the last 90 days
Therasense has some characteristics of a very speculative penny stock
Therasense has a very high chance of going through financial distress in the upcoming years
Therasense currently holds 2.9 M in liabilities. Therasense has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Therasense until it has trouble settling it off, either with new capital or with free cash flow. So, Therasense's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Therasense sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Therasense to invest in growth at high rates of return. When we think about Therasense's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 353.26 K. Net Loss for the year was (7.75 M) with profit before overhead, payroll, taxes, and interest of 256.68 K.
Therasense currently holds about 127.82 K in cash with (5.54 M) of positive cash flow from operations.
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Latest headline from finance.yahoo.com: Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3

Additional Tools for Therasense Pink Sheet Analysis

When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.